Ginkgo Bioworks Hldgs Inc (DNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2001 | 12-2000 | 12-1999 | |
| Cash Flows From Operating Activities | |||
| Net Income | 150,236 | -74,241 | -1,245,112 |
| Depreciation Amortization | 428,091 | 463,004 | 236,365 |
| Income taxes - deferred | 29,357 | -196,782 | -143,371 |
| Accounts receivable | -59,512 | -103,863 | -32,350 |
| Other Working Capital | -127,023 | 123,977 | 149,798 |
| Other Operating Activity | 59,478 | -18,564 | 903,652 |
| Operating Cash Flow | $480,627 | $193,531 | $-131,018 |
| Cash Flows From Investing Activities | |||
| PPE Investments | -213,351 | -112,681 | -53,495 |
| Purchase Of Investment | -1,565,060 | -566,068 | -308,595 |
| Sale Of Investment | 1,084,546 | 574,145 | 505,451 |
| Other Investing Activity | -10,105 | -55,604 | -62,430 |
| Investing Cash Flow | $-703,970 | $-160,208 | $80,931 |
| Cash Flows From Financing Activities | |||
| Common Stock Issued | 106,866 | 180,379 | 95,912 |
| Common Stock Repurchased | -39,704 | N/A | N/A |
| Financing Cash Flow | $67,162 | $180,379 | $95,912 |
| Beginning Cash Position | 551,384 | 337,682 | 291,857 |
| End Cash Position | 395,203 | 551,384 | 337,682 |
| Net Cash Flow | $-156,181 | $213,702 | $45,825 |
| Free Cash Flow | |||
| Operating Cash Flow | 480,627 | 193,531 | -131,018 |
| Capital Expenditure | -213,351 | -112,681 | -53,495 |
| Free Cash Flow | 267,276 | 80,850 | -184,513 |